Socium Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 04-07-2024
- Paid Up Capital ₹ 0.20 M
as on 04-07-2024
- Company Age 9 Year, 8 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
as on 04-07-2024
- Revenue 479.34%
(FY 2017)
- Profit 5816.19%
(FY 2017)
- Ebitda 517.38%
(FY 2017)
- Net Worth 24.84%
(FY 2017)
- Total Assets 668.72%
(FY 2017)
About Socium Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹2.00 M.
Jyoti Kumari, Anand Srivastav, Sanjeev Kumar, and Three other members serve as directors at the Company.
- CIN/LLPIN
U51397DL2015PTC288482
- Company No.
288482
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Dec 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Socium Pharmaceuticals?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyoti Kumari  | Director | 19-Sep-2019 | Current |
| Anand Srivastav | Director | 30-Aug-2016 | Current |
| Sanjeev Kumar | Director | 19-Sep-2019 | Current |
| Ritesh Kumar | Director | 14-Dec-2015 | Current |
| Brajendra Singh | Director | 14-Dec-2015 | Current |
| Achal Sinha | Director | 14-Dec-2015 | Current |
Financial Performance of Socium Pharmaceuticals.
Socium Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 479.34% increase. The company also saw a substantial improvement in profitability, with a 5816.19% increase in profit. The company's net worth Soared by an impressive increase of 24.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Socium Pharmaceuticals?
In 2017, Socium Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Unidare Pharmacueticals Private LimitedActive 1 year 8 monthsJyoti Kumari and Brajendra Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 27 Jul 2020 | ₹2.00 M | Open |
How Many Employees Work at Socium Pharmaceuticals?
Unlock and access historical data on people associated with Socium Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Socium Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Socium Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
